Vivoryon Therapeutics AG (previously Probiodrug) recently raised €8.2m in equity and won a $15m grant from the US NIH to partially fund the US Ph IIb trial in early Alzheimer’s disease (“AD”) for lead asset PQ912, a small molecule inhibitor of the two glutaminyl cyclase (“QC”) isoforms QPCT and QPCTL. This has extended the cash runway to end Q1/2020E and given the company the financial means to start enrolling patients into the PQ912 Ph IIb trial in AD. Separately, a recent Nature Medicine paper ....
13 Jun 2019
Fresh funding for AD. Immuno-oncology optionality explored
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Fresh funding for AD. Immuno-oncology optionality explored
- Published:
13 Jun 2019 -
Author:
Brigitte de Lima, PHD CFA -
Pages:
23
Vivoryon Therapeutics AG (previously Probiodrug) recently raised €8.2m in equity and won a $15m grant from the US NIH to partially fund the US Ph IIb trial in early Alzheimer’s disease (“AD”) for lead asset PQ912, a small molecule inhibitor of the two glutaminyl cyclase (“QC”) isoforms QPCT and QPCTL. This has extended the cash runway to end Q1/2020E and given the company the financial means to start enrolling patients into the PQ912 Ph IIb trial in AD. Separately, a recent Nature Medicine paper ....